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The aims of this research were to prepare highly bioavailable binary cogrounds (vincamine- AcDiSol® or PVP-Cl) by means of a mechanochemical process and to study the mediation of each poliymer in the induction of physical transformations of the drug.
From a set of fifthteen cogrounds for each crosslinked polymer, two samples were selected in each group on the basis of the AUC of in vitro dissolution profiles with the help of a statistical comparison. The chosen samples were analysed by means of TEM, XRPD, Raman-spectroscopy/imaging, SSNMR, also including the study of 1H spin-lattice relaxation times. The research encompassed in vivo oral absorption studies in rats, pharmacokinetic analysis and physical stability studies during 1 year. An intimate drug-polymer mixing was found in the coground samples with domain average dimensions smaller than 100 Å; this reflected in a remarkable enhancement of the in vitro and in vivo bioavailability. Different disordered states were detected in the coground samples as a function of cogrinding time and the type and amount of polymer used.
Though both crosslinked polymers produced a remarkable enhancement of the oral bioavailability, coground systems based on AcDiSol® are preferable in terms of pharmacokinetic performance and physical stability.








Vincamine (VIC), an indole alkaloid originally isolated from the leaves of Vinca Minor L., is an important drug used against brain sclerosis as well as in post-operative states of the central nervous system. VIC main activity concerns vasodilatory effects in the brain, and exhibits also neuroprotective effects by cerebral metabolism reduction and through diminution of the oxygen utilisation. The vasodilatatory and nootropic properties of VIC are of particular interest in neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases (Karpati et al., 2002; Vas and Gulyas, 2005; Vereczkey, 1985). From the physico-chemical point of view, VIC is a highly crystalline powder when recrystallised from acetone or methanol (Budavari et al., 1996). VIC and its derivatives are lipophilic compounds as demonstrated by their octanol-water partition coefficients (Mazak et al., 2003). Due to its pKa of 6.17, VIC shows a pH-dependent dissolution/solubility, being sparingly soluble in intestinal fluid and soluble at a more acidic pH (Emara et al., 2000). Thus, as a consequence of its scarce wettability and low solubility/dissolution in intestinal fluid, VIC suffers from poor oral bioavailability (20%) (Maincent et al., 1986). Whilst for some VIC derivatives (in particular for vinpocetine) several studies have been carried out with the aim to enhance their solubility/bioavailability (Hasa et al., 2011a, 2011b; Iosio et al., 2008; Kata and Lukacs, (​http:​/​​/​www.scopus.com​/​search​/​submit​/​author.url?author=Lukacs%2c+M.&origin=resultslist&authorId=7003299347&src=s" \o "Search for all articles by this author​) 1986; Ribeiro et al., 2007), VIC has been rather neglected by the Pharmaceutical literature. Furthermore, very little information can be found  about its solid-state. At our knowledge, with the exception of its transformation into the corresponding hydrochloride salt form (Ritschel and Agrawala, 1985), no strategies have been reported in literature to improve its oral bioavailability. So far, there is a need to improve VIC solubility and oral absorption. 
In the present study in order to improve VIC solubility and, as a consequence, its oral bioavailability we aimed to induce physical modifications onto the drug. This has been achieved either by forming highly disordered structures such as nanocrystalline or amorphous phases or by obtaining a molecular dispersion of the drug into the carrier. Cogrinding is a solvent-free process that can represent an interesting means to obtain the aforementioned activated structures (Colombo et al., 2009). High levels of mechanical energy are transferred to the loaded powder, provoking sufficient strain in solid particles to cause crystal lattice defects and consequently crystal long order disruption. These phenomena generate metastable structures that can be stabilised by interaction with a suitable stabilising agent (usually a cross-linked polymer) (Colombo et al., 2009; Hsia et al., 1977; Shakhtshneider and Boldyrev, 1999). 
In the present study two cross-linked polymers, polyvinylpyrrolidone (PVP-Cl) and croscarmellose sodium (AcDiSol®) were selected as VIC carriers in virtue of their different physico-chemical properties: the former has an amphyphilic character while the latter is hydrophilic. Due to their different chemical affinity, they are expected to interact in a different way with VIC. Moreover, both carriers are excipients of choice for the purpose of solubility/bioavailability enhancement of a poorly soluble drug. Since several workers have documented interactions between these polymers and drug compounds in solid dispersions and coground environments, the understanding of the mechanism of interaction between VIC and PVP-Cl or AcDiSol®, their different features, and the influence of these differences on the solid-state structure and performances of the new composites was considered as a second focus of this research. Further, their different stabilisation mechanisms with regards to the drug metastable state were also studied. 
During the first phase of the study, binary coground samples based on VIC:PVP-Cl or VIC:AcDiSol® were analysed by dissolution kinetics test (DKT) with the aim of selecting the best performing sample in each group. Then, an in depth examination of the selected coground samples by different solid-state analyses such as transmission electron microscopy (TEM), X-Ray Powder Diffraction (XRPD), Raman Spectroscopy-Imaging and Solid-State NMR Spectroscopy (SSNMR) was carried out. In vivo studies were also performed in order to check the oral bioavailability of selected coground samples. Finally, one year physical stability studies of the selected composites were carried out.


2. Materials and methods
2.1 Materials
VIC was a kind gift from Linnea SA (Riazzino-Locarno, CH). Cross-linked polyvinylpyrrolidone (PVP-Cl) was purchased from BASF (Ludwigshafen, Germany). Croscarmellose sodium (AcDiSol®) was provided by Shilling (Milan, Italy). All other analytical-grade chemicals and solvents of HPLC grade were provided by Carlo Erba (Milan, Italy). 

2.2 Methods
2.2.1  Preparation of coground mixtures (Cog)
Binary systems consisting of VIC:PVP-Cl or VIC:AcDiSol® were coground in 3 drug-to-polymer weight ratios and 4 milling times selected during preliminary trials. Three VIC:PVP-Cl or VIC:AcDiSol® weight ratios were considered, as following: 1:2, 1:4 and 1:7, and, as milling times: 45, 90, 120 and 180 min. For each polymer used, 12 different composites and 3 physical mixtures were prepared. The grinding process was performed in a planetary mill Fritsch P5 (Pulverisette, Contardi Fritsch s.r.l., Milan, Italy) which was equipped by 4 agate cylindrical grinding chambers (internal height Hv=2.6 cm, internal radius Rv=3.2 cm, internal volume = 27.5 cm3). As grinding media, agate balls having a 2.2 cm diameter were adopted. 
 In order to maximize the energy transfer from the mill to the loaded powder, via the grinding media, the grinding process was optimised according to a previously published mathematical model (Voinovich et al., 2009b). Hence the following process conditions were adopted: maximum velocity and number of grinding media (6 agate balls). As for the bowl loading the weight depended on the relative amount of the components, and resulting volume of the mixture, obtaining a mean weight of 3.7g and 4.5g for the VIC:PVP-Cl or VIC:AcDiSol® systems, respectively. Based on previous experiences, the grinding process was stopped every 15 min for homogeneously mixing the mass with a stainless steel spatula (Voinovich et al., 2009a, 2009b). 

2.2.2 Preparation of physical mixtures (PM)
Physical mixtures (PM) were prepared in batches having mean weights of 20 g and 25 g for VIC:PVP-Cl or VIC:AcDiSol® systems, respectively, by manually mixing drug and polymer with a stainless steel spatula for the standardised time of 8 min. The component weight proportions were the following: 1:2, 1:4 and 1:7 w/w. Then a mean weight of 3.7 g and 4.5 g for VIC:PVP-Cl or VIC:AcDiSol® (the weight depends on the relative amount of the components and resulting volume of the mixture) were used for cogrinding experiments, and the rest was used as PM for comparison purposes (X1=0 in Table 1).

2.2.3 X-ray Powder Diffraction Studies (XRPD)
XRPD patterns were recorded using a D500 (Siemens, Munich, Germany) diffractometer with Cu-K radiation (1.5418 Å), monochromatised by a secondary flat graphite crystal. All the analyses were performed in duplicate using a current at 20 mA and the voltage was set at 40 kV. The powder samples were scanned in the range from 5 to 35° of 2 angle, steps were of 0.05° of 2, and the counting time was of 5 sec/step.

2.2.4 Raman imaging/spectroscopy 
Raman spectra and images were acquired for coground composites, PM and pure components  using an inVia Raman system (Renishaw plc, Wotton-under-Edge, UK), equipped  with a 300 mW  diode NIR laser emitting at 785 nm (Renishaw) and a ProScanTMII motorised stage (Prior,  Cambridge, UK). The laser was focused on the sample (consisting  of  300-mg tablets with flat  surfaces, prepared from physical  and coground mixtures having different drug-to-polymer weight ratios, and from pure components) by a 50X objective (0.75 N.A.). To ensure a better sampling for each tablet by taking into account local variations in composition, an area of 84×84 μm was mapped with a grid of 2.8 μm (corresponding to 900 spectra per map) for each sample, using the StreamlineTM fast imaging configuration and the WiRE 3.1 software (Renishaw), with a total collection time of 13 min/map. Raman maps were then pre-processed (cosmic rays removal and baseline correction) and analyzed with the HyperSpec software package (Beleites and Sergo, 2009) for R (R Development Core Team, 2009), an average spectrum was calculated for each map, and images depicting the intensity ratio between the 1600 cm−1 band of VIC and a band characteristic of the polymer (at 1668 cm−1 for PVP-Cl and at 1397 cm-1 for AcDiSol®, respectively) were produced.

2.2.5 Solid-state Nuclear Magnetic Resonance (SSNMR) spectroscopy
SSNMR spectra were recorded on a Bruker Avance II 400 instrument operating at 400.23, 100.64 and 40.55 MHz for 1H, 13C and 15N nuclei, respectively. Cylindrical 4 mm o.d. zirconia rotors with a sample volume of 120 μL were employed and spun at 12 (13C) and 7 (15N) kHz. A ramp cross-polarisation pulse sequence was used with a contact time of 3-4 ms, a 1H 90° pulse of 2.9 μs, recycle delays of 8 s, and 1000-30000 transients. A two pulse phase modulation (TPPM) decoupling scheme was used with an rf field of 75 kHz. 13C and 15N chemical shift scales were referenced with the resonance of hexamethylbenzene (13C methyl signal at 17.4 ppm) and (NH4)2SO4 (15N signal at 355.8 ppm with respect to CH3NO2). Spectral editing experiments were performed by using a CPPISPI pulse sequence with a polarization inversion time of 85µs in order to obtain CH3 and Cq positive, CH null and CH2 negative. Proton spin-lattice relaxation times, 1H T1, were obtained by the 13C-detected Inversion Recovery Cross Polarisation technique [1H(180°--90°)-CP-13C(FID)], where one measures the 13C magnetisation that appears through the CP process after relaxation of the 1H magnetisation during the time .

2.2.6 Dissolution kinetic tests (DKT) 

Dissolution kinetic tests were performed in triplicate. The dissolution medium was 150 cm3 of 0.2 M KH2PO4/0.2 M NaOH (pH 7.4) at 37°C, since VIC solubility is pH-dependent and is particularly poor in intestinal buffer. According to Nogami et al. (1969), non-sink conditions were attained in release environment (Cs= 41.6 mg/L, see below) adding a suitable amount of pure drug or binary system to give 20 mg concentration of active ingredient to the release environment at time zero. Each release test lasted 180 min. Uniformity conditions were ensured by an impeller (stirring rate 200 rpm). The use of a fiber optic apparatus (HELLMA, Milano, Italy), connected to a spectrophotometer (ZEISS, Germany, wavelength 268.49 nm), allowed the determination of VIC concentration without perturbing the dissolution environment. Moreover, this methodology allowed to easily overcome the problem connected to drug concentration measurement in presence of a dispersion of solid particles. The scattering effect due to polymeric particles occurred at every wavelength (both PVP-Cl and AcDiSol® are insoluble polymers), while VIC absorbed at 268.49 nm. No Tyndall effect was observed. Moreover, the dissolution vessel was covered by an aluminum foil to avoid additional scattering effects. Thus, to calculate the real absorbance related to VIC concentration, the difference between the absorbance measured at 268.49 nm and that measured at 500.49 nm (at 500.49 nm vincamine did not absorb) was computed. Results were the average of three replicates. 

2.2.7 Solubility studies
VIC solubility at equilibrium (Cs) was determined by adding an excess of pure VIC (2 g) in 150 cm3 of pH 7.4 buffer (0.2 M KH2PO4/0.2 M NaOH) maintained at 37°C and stirred at 200 rpm. The solutions were then assayed using the same fiber optic apparatus used for DKT and absorbance measurements were recorded at 268.49 nm for 36 h. The adequate time for equilibration was reached after 26 h of testing. The experiment was performed in triplicate and the mean value ± S.D. obtained was recorded.

2.2.8 Transmission Electron Microscopy (TEM) 
The samples were post fixed in 1 % osmium tetroxide for 12 hour at 4°C and embedded in Dow Epoxy Resin (DER 332). Ultrathin sections were cut by an ultratome Leica Ultracut UCT8 (Leica, Mikrosysteme Aktiengesellschaft, Wirn, Austria), double stained with uranyl acetate and lead citrate and examined with a Philips EM 208 transmission electron microscope (Philips, Eindhoven, the Netherlands) with an accelerating voltage of 100 kV. Images were acquired using an Olympus Morada CCD camera.

2.2.9 In vivo absorption studies
All the procedures for rats care and management performed in this research complied with those required by Italian laws (D.L.vo 116/92) and associated guidelines in the European Communities Council Directive of 24 November 1986 (86/609 ECC) and adhered to ethical standards for humane treatment of experimental animals established by the ethical committee of University of Trieste. 
Sprague-Dawley rats (400-450 g weight) were fasted, with free access to water, 12 hours before the experiment. The coground systems and physical mixtures were administered as aqueous suspensions (2 ml corresponding to a dose 20 mg/kg of VIC) by gastric gavage. Each experimental formulation was tested on 4 rats. The kinetic experiment lasted 8 hours. Blood samples (600 l) were obtained using the “cannulated” tail artery method (Cadelli and Zarattini, 2007). Blood collection was performed (using tubes containing 66l of a 40 mM tetrasodium EDTA solution) at 0.5, 1, 2, 4, 6 and 8 hours after administration. After collection, the samples were centrifuged at 166 g for 10 min and plasma was separated and immediately frozen at -80°C, and stored at this temperature till the analysis.

2.2.10 Assays of VIC in powder and plasma samples
Sample preparation
The drug content in the PM, coground systems and pure VIC was determined as following: a suitable amount of powdered sample was weighed and transferred to a 100 ml volumetric flask and diluted with acetonitrile. The mixture was sonicated for 10 min and filtered through a syringe filter (RC 0.45 µm, Phenomenex, Castel Maggiore, Bologna, Italy) to remove any particle. An appropriate amount of the filtrate was subjected to a further dilution with acetonitrile and then assayed by high pressure liquid chromatographic (HPLC) with a mass spectrometry (MS) detection method described into details in the following paragraph.
Conversely, for the determination of VIC in plasma samples, 600 L methanol were added to 200 L plasma, and the resulting mixture was vortexed for 6 min. After centrifugation (1800 g for 13 min), 5 L of the solution was injected. The VIC determination in plasma samples was carried out using the same HPLC-MS method.

2.2.11 HPLC analysis
The HPLC system used is a Varian LC212 equipped with 430 autosampler and with a 500-MS mass detector. The chromatographic separation was performed at room temperature, using an Agilent C-8 (2.1 x 150 mm) column. For the mobile phase was used acetonitrile (Solvent A) and water with 0.1% formic acid (Solvent B) which was delivered at a flow rate of 200 L/min. Gradient elution was used starting from 90% B then in 5 minutes to 100% A. The total run time was 8 min. The mass spectrometer operated in the positive ion mode with a needle voltage of 5000 V and a spraying voltage 600 V. Other MS conditions are: drying temperature was 350°C, nebuliser gas pressure was 25.0 psi; drying gas pressure was 15.0 psi; precursor ion at m/z 355 and parent ion at m/z 337 were selected in MS/MS mode. Calibration curve for VIC consisted in different standard solutions (prepared and analyzed in duplicate) ranged from 8 to 640 ng/mL. The limit of quantification was 2 ng/mL and the precision and accuracy were under 3% for all calibration points.

2.2.12 Pharmacokinetic analysis
Following initial graphical exploration of the individual VIC plasma concentration profiles on the semilogarithmic plots, VIC pharmacokinetics were assessed by fitting a one-compartment model with first order absorption and elimination. ADAPT 5 (Build 5.0.35, http://bmsr.usc.edu (​http:​/​​/​bmsr.usc.edu​)) software (D’Argenio et al., 2009) and the maximum likelihood method were used to estimate absorption rate constant (ka), apparent oral clearance (CL/F) and volume of distribution (V/F). The variance model was:
									(1)
where Vi is the variance of the i-th data point, 1 and 2 are variance model parameters, and Ĉi is the predicted concentration. Goodness of fit was estimated by visual inspection of the fitted curves. Secondary parameters, including absorption and elimination half-lives (t1/2ka and t1/2ke), area under the plasma concentration versus time curve (AUCin vivo), maximum concentration (Cmax), time to reach maximum concentration (tmax) and time span during which concentration is at least 75% of the maximum concentration t75% Cmax were calculated by conventional algorithms.





In order to check possible modifications of the solid state (e.g. recrystallisation) within time, XRPD and DKT analyses of the selected composites were repeated every 4 months for a period of 12 months. Throughout the study the solid samples were kept at 25°C in a desiccator. 

3. Results and Discussion
3.1 Selection of the best performing samples
During preliminary trials, as a matter of comparison for the coground systems, VIC was processed alone in the planetary mill at the same operative conditions subsequently used for the preparation of the coground samples. VIC did not change remarkably its features when subjected alone to the mechanochemical process, and maintained a highly crystalline character even after 180 min of grinding. In fact, original VIC showed its melting point at 240.9°C (as determined by means of a differential scanning calorimeter (DSC) Mod. TA 4000, equipped with a measuring cell DSC 20 Mettler, Greifensee, CH, at 10°C/min). Instead, after 180 min of milling VIC melting point was 236.6°C (Fig. 1).
In the XRPD pattern of original VIC several distinct signals (for example at 8.10, 10.50, 12.65, 14.05, 17.60, 23.15° of 2θ) were observed in the range of analysis. These reflections did not change remarkably their intensity after 180 min of milling and in the diffractogram of the ground sample there was no evidence of polymorph formation (Fig. 1). Accordingly, very small differences between the original sample and VIC processed for 180 min were detected at the DKT (Fig.1), and both profiles were largely inferior to the Cs (41.6 ± 1.3 mg/L) of the drug in pH 7.4 buffer (dotted line).
It is hence likely that only minor changes in the drug solid-state features (morphology and crystal packing) were obtained after processing VIC alone. These changes probably consist in a particle size reduction, in a small increase of surface area and only in a slight reduction of the crystallinity degree. A probable reason for the latter is that the crystal defect zones generated are too small and their propagation is counteracted by the tendency to return in the ordered crystalline structure. Another factor for the inefficient grinding process can be related to remarkable phenomena of adhesion to the chamber walls and to the grinding media. This resulted in a very hard layer of VIC which probably inhibited the energy transfer needed for the mechanochemical process itself. The same phenomena have been previously observed processing pure vinpocetine (a VIC derivative) (Hasa et al., 2011a) and a dry extract alone (Voinovich et al., 2009a, 2009b).
Thus, it is advisable to grind VIC in presence of a polymeric carrier in order to obtain satisfactory results in term of dissolution rate. The two selected polymers have also demonstrated their efficacy to improve dissolution properties and bioavailability of poorly soluble drugs (Carli et al., 1986; Shin et al., 1998) and to stabilise for a long period the activated meta-stable structures generated by the mechanochemical process.
Consequently, VIC was coground in presence of PVP-Cl or AcDiSol® for 4 different milling times and in 4 drug-to-polymer weight ratios, selected during preliminary trials, as reported in Table 1. Usually drug-to-polymer weight ratio and milling time variables are the most influencing factors on the drug crystal lattice disruption. For this reason the preliminary trials are of a crucial importance in order to select the formulation that offers the best performance (in terms of dissolution rate) with a minimum energy spent (milling time) and with the optimal drug-to-carrier weight ratio (in terms of stability and dispersive effects). Another important parameter is the optimisation of the milling process itself. In this way it is possible to ensure a higher energy transfer from the grinding media to the loaded powder, by optimisation of the operating conditions (powder mass loading, number of grinding media, rotation velocity, etc.) with the help of a mathematical model (Voinovich et al., 2009b). 
In the planetary mill the co- or counter-movement of the rotating plate and the vials generates a disordered movement of the grinding media. Consequently, a high mechanical energy is produced and then transferred to the loaded powder. This energy creates disorder in specific zones of the original VIC crystal lattice and, as a consequence, the formation of activated metastable structures which are fixed into the network of the cross-linked polymer. As a consequence the “activated” drug will result prone to the dissolution media. 
Thus, in order to select the best performing composites, the 24 coground samples produced (12 for each polymer) were subjected to DKT and compared to their corresponding PM. Since it was expected that the formulation having the higher degree of VIC of activated structures will show a faster and higher dissolution rate, the area under the curve of solubilised concentration vs. time from t=0 min to the last measuring point (180 min) (AUC0-180) was calculated and used as a parameter to evaluate the degree of activation of the samples. The results are listed in Table 1 (as AUC0-180 ± S.D.; n=3) for all the coground samples and PM. 
Further, to make a comparison among the performed samples, the FDA bioequivalence limits were adopted. In particular, the FDA guidance suggests that two compounds/formulations can be considered bioequivalent if the ratio of their AUCs is included in the 0.80 – 1.25 interval (FDA, 2003). This evaluation parameter is proposed for in vivo studies, but it seems useful also in the present case to compare AUC values obtained from in vitro data. The formulations with AUC included in the above mentioned interval will be considered in vitro equivalent instead of bioequivalent. 
For each polymer, the higher AUC value was recognised and indicated as AUCmax. Further, the ratio (indicated as Z) between the AUC of each formulation and AUCmax was calculated as following:

                                                                                                         (3)

For all the Z ratios the associated uncertainty (indicated as dz) was calculated with the classical formula of the relative error of a ratio (Taylor, 1997):

                (4)

where dAUCformulation and dAUCmax signify the S.D. of the AUCformulation and AUCmax values, respectively (Table 1). All the Z ± dz values are listed in Table 1 and represented graphically in Fig. 2. For a more restrictive selection only coground formulations having a Z value higher than 0.85 (instead of 0.80) were considered for further examinations. 
Looking at Table 1 and Fig. 2 the following coground samples showed the maximum AUC value (AUCmax): VIC:PVP-Cl 1:4 wt ratio coground for 180 min (formulation 10, Fig. 2A) and VIC:AcDiSol® 1:7 wt ratio coground for 180 min (formulation 15, Fig. 2B). Other two samples resulted to be equivalent to these formulations: VIC:PVP-Cl 1:7 wt ratio coground for 180 min (formulation 15 in Fig. 2A) and VIC:AcDiSol® 1:7 coground for 120 min (formulation 14 in Fig. 2B). 
Based on Fig. 2 and Table 1, further considerations can be conducted. In the case of VIC:PVP-Cl composites, the milling time seems to be the most influencing parameter on drug dissolution (Fig.2A). In fact the AUC value increased in a linear mode as the milling time increased (Table 1). Thus, by using an amphyphilic polymer, like PVP-Cl, the VIC crystal lattice disruption, and hence the interaction between drug and polymeric carrier, is influenced by the energy supplied to the powder mixture. However it is not advisable a milling procedure longer than 180 min because a series of undesired effects can appear, such as, for example, particle agglomeration, with predictable negative effect on the dissolution performance of the coground sample (Shakhtshneider and Boldyrev, 1999). 
Looking at the dissolution profiles (data not shown) and at the Z values a further peculiar phenomenon can be noticed: the 1:7 VIC:PVP-Cl w/w binary mixtures processed for different grinding times showed a dissolution performance of lesser entity compared to corresponding 1:4 VIC:PVP-Cl w/w. This behavior is consistent in all the grinding times. These decreasing of dissolution could be ascribed to the formation at high polymer concentrations of a high viscous layer around the particles of the drug (Moneghini et al., 1998). Further possibilities of relevance are also the presence of VIC in different solid states in the 1:7 and 1:4 w/w samples or the formation of less soluble complexes (quite common in PVP derivatives) in a precise stoichiometric ratio, whose existence in the present case will be investigated during further physico-chemical analyses. 
In the case of VIC:AcDiSol® composites the scenario was completely different: drug-to-polymer ratio variable seems to be the most important parameter. Indeed at higher milling times the Z value of composites doesn’t change noticeably (Fig. 2B composites number 2-6). Increasing drug-to-polymer weight ratio, the Z value increased and, at the same time, the milling time parameter became more important (Fig. 2B composites number 12-15). Subsequently a plateau was reached, thus indicating the maximum level of activation was obtained.
Therefore, from the screening analysis, the systems selected for further considerations were the VIC:PVP-Cl 1:4 and 1:7 wt ratio coground for 180 min and VIC:AcDiSol® 1:7 wt ratio coground for 120 and 180 min. For the sake of brevity, here below these samples are named Cog 180 min VIC:PVP-Cl 1:4 wt, Cog 180 min VIC:PVP-Cl 1:7 wt, Cog 120 min VIC:AcDiSol® 1:7 wt and Cog 180 min VIC:AcDiSol® 1:7 wt respectively. 

3.2 Evaluation of the selected samples
3.2.1 Solubilisation kinetics and TEM analysis
Mean dissolution profiles (n = 3) at pH 7.4 of the selected coground samples are shown in Fig. 3, compared to pure VIC and corresponding PM.
It can be observed that a very small dissolution improvement can be obtained by the simple PM with both the polymeric carriers (Fig. 3), mainly attributable to the facilitated drug wettability and drug dispersion in the dissolution medium. However, the extent of solubilised VIC remained far below the solubility at equilibrium (Cs) of VIC (Fig. 3 dotted line).
Looking at the dissolution profiles of VIC:PVP-Cl composites, different solubilisation kinetics are observed: whilst a very pronounced supersaturation phenomenon was noticed in the Cog 180 min VIC:PVP-Cl 1:7 wt, the Cog VIC:PVP-Cl 1:4 wt DKT showed only a slightly supersaturation followed by a plateau of drug concentration. This fact suggests a different physical state of the drug in the 2 coground samples and a different capacity of the polymer depending on its concentration to stabilise the poorly soluble drug in solution. A supersaturated solution is compatible with the presence of an amorphous state, which is then followed by desupersaturation as a result of crystallisation of the drug from the solution phase (Alonzo et al., 2009). Based on these speculations it is expected a higher amorphous state in the Cog 180 min VIC:PVP-Cl 1:7 wt. If this is the case, the contribution of PVP-Cl on inhibition of crystallisation tendency is poor and it is also possible that during dissolution test PVP-Cl may reduce dissolution due to high viscosity in the boundary layer adjacent to the dissolving surface, as previously noticed (Moneghini et al., 1998). 
The observation of the dissolution profiles of VIC:AcDiSol® coground samples reveals that the highest amount of solubilised VIC - nearly 5 times than that of pure VIC - was reached and maintained for all the test duration. Differently from the VIC:PVP-Cl, no supersaturation phenomena were observed, suggesting the absence of amorphous VIC in this case and the higher capability of AcDiSol® of impeding crystallisation in solution. This is in accordance with previous studies where linear PVP was found less effective than cellulose derivatives at maintaining drug in solution (Alonzo et al., 2009; Konno et al., 2008). In addition, the polymeric carriers used in this case have different chemical properties, therefore VIC can probably penetrate deeply or being molecularly dispersed in the PVP-Cl cross-linked network due to similar chemical affinity: VIC is a lipophilic compound (Log P = 3.03 (Mazak et al., 2003)) whilst PVP-Cl is an amphiphilic polymer. Instead, AcDiSol® has a pronounced hydrophilic character so the drug miscibility with this polymer and penetration structures inside the cross-linked network are expected to be lower. This in turn results in a difference in the energy (and therefore time) required to bring the drug from the solid phase into the solution phase. This hypothesis was confirmed by observation of TEM images of the same samples (Fig. 4). In fact, it seems that the drug in the VIC:AcDiSol® composites was mainly located on the surface of the polymer (Fig. 4C and D). Conversely, in the VIC:PVP-Cl coground systems the active is embedded inside the cross-linked network. This latter situation implies that the polymer would mainly control dissolution, since the drug, before dissolution, must diffuse through the polymer. This diffusion kinetic is influenced by the swelling and rheological properties of the polymer, and the higher the time requested for diffusing the higher the possibility for the drug to recrystallise during diffusion (Grassi et al., 2007). 
The observation of Fig. 4 gives origin to further considerations: the active in the VIC:PVP-Cl coground samples seemed to be prevalently in an amorphous form or in a molecularly dispersed state, whilst in VIC:AcDiSol® coground samples it appeared to be mainly in a nanocrystalline status. To further elucidate this point, the solid-state features of the selected composites were studied by XRPD, Raman spectroscopy and imaging and SSNMR spectroscopy. On the contrary, DSC analysis did not provide reliable information since the drug melting point was superimposed to the thermal event of the degradation of the polymers (both starting from 180°C). 
3.2.2 XRPD analysis
The XRPD patterns of raw materials, selected cogrounds and corresponding PM are shown in Fig. 5.
The polymeric carriers showed a complete lack of peaks and a halo pattern indicating their complete X-ray amorphous status (Fig. 5a), while pure VIC showed, as afore mentioned, intense reflections indicating its crystalline nature. 
In the XRPD pattern of VIC:PVP-Cl PM and VIC:AcDiSol® PM (Fig. 5c), the VIC characteristics peaks emerged, indicating that the simple mixing process did not affect the crystalline structure of VIC.
In the coground systems, a general broadening and/or disappearing of VIC diffraction pattern was recognised. In particular, in the case of  the Cog 180 min VIC:PVP-Cl 1:4 wt pattern, VIC diffraction peaks having low intensity were still detectable (Fig. 5d left), suggesting the presence of VIC crystals in the nanometric order. Conversely, the Cog 180 min VIC:PVP-Cl 1:7 wt was a X-ray amorphous solid material (Fig. 5f left).
In the case of VIC:AcDiSol® coground systems a dramatic reduction of drug signal intensity, a broadening of the reflections, and a remarkable scattering phenomenon was noticed. These facts were evidence of the conversion of the original VIC crystal lattice into an amorphous and/or nanocrystalline phase (Fig 5 d) and e) right)).
In the next step a solid-state characterisation was pursued with the aim of studying nature and strength of interactions between VIC and each polymeric carrier. For this purpose Raman and SSNMR analyses were carried out.

3.3.3 Raman spectroscopy/imaging
First of all, the effect of the co-grinding process on the spatial heterogeneity of the mixtures at microscopic level was evaluated with Raman imaging. Raman images depicting the distribution of vincamine in PM and coground tablets prepared using PVP-Cl or AcDiSol® clearly indicated that coground samples have a more homogenous drug distribution than PM (Fig. 6). Among the coground samples, the most homogeneous sample is the Cog 180 min VIC:PVP-Cl 1:7 wt, followed by the Cog 180 min VIC:PVP-Cl 1:4 wt and Cog 180 min VIC:AcDiSol® 1:7 wt. Conversely a lower spatial homogeneity was observed in the case of Cog 120 min VIC:AcDiSol 1:7 wt, corresponding to the sample subjected to a shorter grinding time. 
Raman spectra of PM, for both PVP-Cl and AcDiSol® (Fig. 7), are a superposition of the pure components, suggesting the lack of interactions between VIC and polymers. For VIC:AcDiSol® samples, Raman spectra of the cogrounds are also remarkably similar to those of the PM and pure components: the absence of shifts of the bands indicates that in both PM and coground samples the average chemical environment of VIC remains largely unaffected by the co-grinding process. This lack of spectral differences could be explained by the nanocrystalline nature of the VIC:AcDiSol® coground samples, as suggested by TEM and XRPD data. Assuming the occurrence of crystallites larger than 5 nm, Raman spectra are expected to be identical to those obtained from larger microcrystals (Gouadec and Colomban, 2007). 
Considering the large presence of the amorphous form in the coground VIC:PVP-Cl samples, as inferred from XRPD data, their Raman spectra are surprisingly similar to those of the PM and pure components. While no shifts in band positions are detected, a very small broadening of the VIC band at 1600 cm-1 is observed in the spectra of coground VIC:PVP-Cl samples, suggesting the occurrence of slight variations in the intermolecular interaction between VIC and the polymer, possibly due to an increase in molecular disorder. 

3.2.4 SSNMR spectroscopy
Owing to a multinuclear approach and short-range rather than long-range order sensitivity, the SSNMR spectroscopy represents a complementary technique with respect to XRPD and Raman analyses (Braga et al., 2007). It can easily provide information on weak interactions, such as hydrogen bonding, and on the local environment at each specific site (Chierotti and Gobetto, 2008). Furthermore, 1H T1 relaxation analysis allows estimating the homogeneity or heterogeneity of a mixture of two or more components over a 100 Å scale.
The 13C CPMAS spectrum of VIC is shown in Fig. 8 together with the spectral editing experiment which allows an accurate peak assignment according to the signal phase (CH3 and Cq positive, CH null and CH2 negative). 13C and 15N SSNMR signal assignments, based on spectral editing experiments (Fig. 8), are reported in Table 2 and refer to the atom labeling depicted in Fig. 8.
The 13C CPMAS NMR spectra of raw materials, selected coground and PM samples are shown in Fig. 9.
The 13C CPMAS spectra of PM systems, both with PVP-Cl (Fig. 9c left) and AcDiSol® (Fig. 9c right), are simply the weighted superposition of the pure component spectra. Thus, no significant modifications in both drug and carrier molecular properties occur following their mixing, and therefore no detectable interactions between the two components take place in agreement with XRPD and Raman analysis. In particular no changes have been observed for the signals ascribed to C14 (82.6 ppm) that revealed to be very sensitive to the hydrogen bond N···H-O characterizing the VIC crystal packing (Fig. 11).
On the other hand, the linebroadening observed in the coground samples is related either to a larger distribution of isotropic chemical shifts, arising in turns from a distribution of chemical environments for the same carbons belonging to different drug molecules or to a considerable alteration of the molecular dynamics of the drug caused by the grinding with the polymer. In any case, this is a clear indication of a strong drug-polymer interaction occurring in the coground samples.
However, if the linebroadening had a dynamic nature, on one side the motional process should involve the whole drug molecule, since all the signals are broaden; on the other side, the linebroadening should be due to some interference of a typical motional frequency with an instrumental frequency, such as the magic angle spinning or decoupling ones (Chierotti and Gobetto, 2009). The amorphous state detected by XRPD (see above) and the lack of changes in the line widths in NMR spectra performed at different spinning and/or decoupling frequencies safely ruled out this hypothesis. Therefore the linebroadening should be explained in terms of a wider distribution of chemical environments that is expected from either a reduction of the particle size (which leads to an increase of the surface/volume ratio and thus of the drug-polymer interaction) or a more disordered molecular packing or, in some coground cases, the amorphous nature. 
The main difference between VIC:PVP-Cl and VIC:AcDiSol® coground spectra consists in the broadening degree which is wider in the former (difference of about 100 Hz for the signals around 119 ppm). This indicates a higher degree of interaction in the VIC:PVP-Cl than in the VIC:AcDiSol® system due to smaller particle sizes as confirmed by 1H T1 measurements (see below).
Concerning the 15N CPMAS spectra, no shifts are observed for the two nitrogen atoms in the coground and PM samples (Fig. 10). It is worth noting that the chemical shift of N4 (12.0 ppm) is intermediate between the protonated and deprotonated values (19 and 4 ppm, respectively) (Hasa et al., 2011b) in agreement with the presence of a N···H-O hydrogen bond interaction in both pure VIC and VIC:polymer samples (Gobetto et al., 2005). Due to the higher chemical affinity between VIC and PVP-Cl, the detection of more pronounced drug-polymer interactions in these coground systems is not surprising. 

3.2.4.1  1H T1 relaxation times
The degree of mixing between the two components (VIC and either PVP-Cl or AcDiSol®) of the solid dispersions has been investigated through the measurement of proton spin-lattice relaxation times in the laboratory frame (1H T1) under high-resolution experimental conditions. Indeed, in solid samples the transfer of spin energy among nuclei through homonuclear dipolar couplings becomes much faster than the transfer of energy to the lattice. This process, known as spin diffusion, results in longitudinal relaxation rates of protons within the molecule which all tend to the same value (Ando and Asakura, 1998). This average is usually complete when protons belong to the same phase or in the case of homogeneous samples on a 100 Å scale. On the other hand, different relaxation times can be measured for protons belonging to different domains when these domains have average linear dimensions greater than 100 Å (Geppi et al., 2008). This average is usually complete when protons belong to the same phase or in the case of homogeneous samples on a nanometer scale. Modern understanding of spin-diffusion and of its effects of relaxation suggests a complex dependence on structure and dynamics (Brus et al. 2002).  However, in a more simplified approach, it can be suggested that protons with different relaxation times belong to different domains having average linear dimension greater than about 100Å and viceversa.(Geppi et al., 2008). 
Owing to the low resolution achieved in 1H spectra, even in fast MAS conditions, 1H T1 relaxation times were measured exploiting the high resolution of the 13C spectra, by means of the Inversion Recovery CPMAS experiment. This allows obtaining 1H T1 values of the VIC or of the polymer protons even in homo- or heterogeneous mixture by looking at the 13C VIC or polymer signals, respectively. The results are shown in Table 3. In the experiments performed on the pure components a single T1 value was measured for all the protons, as expected. According to previous DSC, XRPD and DKT results (see Fig. 1), when VIC was ground alone did not change remarkably its 1H T1 value, confirming that the crystal structure was substantially maintained. PM VIC:PVP-Cl 1:4 wt has been chosen as representative PM compounds. As expected two 1H T1 values (5.1s for VIC and 1.5s for PVP-Cl) have been found very similar to that of the pure components (5.2s for VIC and 1.4s for PVP-Cl). This highlights the heterogeneous character of the sample with separated domains larger than 100 Å. In other words either VIC and PVP-Cl preserve the same packing than in the pure samples with very few and weak VIC:PVP-Cl interactions at the surface. Again, a single relaxation time was measured for all the protons (VIC and polymer protons) in all the coground samples. These results clearly indicate that drug and polymer are intimately mixed in the ground mixtures with domain average dimensions smaller than 100 Å. The samples result homogeneous on that spatial scale, in agreement with that previously deduced from 13C NMR. and Raman imaging data. 
To go into more details, in the Cog 180 min VIC:PVP-Cl 1:7 wt the VIC crystal lattice is completely disrupted and is replaced by a drug in an amorphous state or molecularly dispersed in the polymer with a very high VIC-polymer interaction degree. This is also in accordance with the results of Raman imaging and XRPD analysis where a single uniform colour (Fig. 6) and a halo pattern were detected, respectively.
A lower degree of mixing could be recognised in the Cog 180 min VIC:AcDiSol® coground system, even though the domain dimensions were still below 100 Å. This fact is in concordance with previous TEM images (Fig. 4) and XRPD results attesting a VIC prevalently in a nanocrystalline state. The most pronounced differences between the relaxation times of the two components were observed in the case of the Cog 120 min VIC:AcDiSol® in accordance to the fact that this sample was co-milled for a shorter period of time. 

3.2.5  In vivo studies 
To evaluate the effect of cogrinding on the bioavailability of VIC, a pharmacokinetic study in rats with oral administration of the 4 selected coground systems and the corresponding physical mixtures was performed. Plasma concentration profiles are presented in Fig. 12. Pharmacokinetic parameters are summarised in Table 4. The pharmacokinetic profiles generally show a monoexponential decline, although some tendency of biexponential decline can be observed with AcDiSol® coground systems. One-compartment model was selected for the analysis, based on favourable Akaike Information Criterion (AIC) compared to the alternative two-compartment model. Due to limited data in the absorption phase, a first-order absorption model was used and the alternative absorption models were not investigated. As indicated in Fig. 12, VIC plasma concentration profile is notably affected by cogrinding. Comparison of the AUC values reported in Table 4 reveals that mechanical activation of VIC in presence of polymers resulted in improved bioavailability compared to physical mixtures. Relative bioavailability ranged between 3.23 and 4.43 which is in line with the in vitro dissolution data. Furthermore, the plasma concentration profiles considerably differed in the absorption rate. As evidenced by the estimated absorption rate constants and times to maximum concentration, coground systems are generally characterised by more rapid absorption phase. Particularly fast absorption of VIC was observed with coground systems containing hydrophilic AcDiSol®. On the other hand, cogrinding with PVP-Cl which is amphyphilic a more retained release of VIC is obtained, especially in the Cog 180 min VIC:PVP-Cl 1:7 wt. 
Elimination half-life with physical mixtures generally ranged between 1.66 and 2.60 h, which is in accordance with the previous study in rats (EMEA Vincamine Summary Report, 2010), where an elimination half-life of 1.71 h with oral and 1.68 with intravenous dosing is reported. Additionally, it is interesting to note that the elimination half-lives with the coground systems are longer compared to the corresponding physical mixtures. This may reflect in delayed slow absorption of VIC following the initial burst. This is primarily evidenced with PVP-Cl, which is again in agreement with the physicochemical characteristics of the polymer.
Comparison of the oral bioavailability of the coground systems with the corresponding physical mixtures revealed the superior performance of the mechanochemically activated systems with evident improvement in the extent of VIC absorption. Moreover, the in vivo results were in parallel with the in vitro data as revealed the Z ± dz values showed in Table 4. This indicates that bioavailability of the coground systems can be predicted based on results of in vitro experiments. Additionally, we demonstrated that the behavior of the two systems in vivo was remarkably different. AcDiSol® coground samples exhibited very high Cmax and short tmax, followed by a quite rapid decrease of plasma concentration, while on the other hand, with PVP-Cl coground samples flatter plasma concentration profiles over 8 h period were observed. Further, this behavior is in line with a preponderant location of the drug on the surface of the polymer in the case of VIC:AcDiSol® and molecularly dispersed or embedded in the cross-linked network in the VIC:PVP-Cl coground systems.

3.2.6  Physical stability studies
The drug solid-state features in the selected coground samples was studied by repeating the XRPD and DKT analyses every 4 months for a period of 1 year (Figs. 12 and 13). These two techniques were chosen because of their complementary nature: evidence of drug recrystallisation would procured alteration of the solubilisation kinetics and intensification, with sharpening, of the XRPD peaks. Further in the present case, these two techniques have resulted to be the most effective in detecting differences among AcDiSol® and PVP-CL coground physical states. 
The coground systems based on PVP-Cl, peculiarly the Cog 180 min VIC:PVP-Cl 1:7 wt, gave evidence of the formation of more ordered structures upon storage. In fact, a progressive transformation of VIC from an amorphous or molecularly dispersed state into a nanocrystalline phase emerged from the comparison of the XRPD and DKT results. As expected, less dramatic structural changes after 1 year are visible in the Cog 180 min VIC:PVP-Cl 1:4 wt. Indeed, in this system the drug was initially present in a nanocrystalline state, that is disordered solid lacking of long-range crystalline order but with retained hydrogen bond motif of the parent crystalline form, representing an intermediate state between a crystal and an amorphous or molecularly dispersed state.
Differently from the VIC:PVP-Cl systems, the coground based on AcDiSol® resulted very stable upon storage (1 year). The most stable system resulted to be the Cog 180 min VIC:AcDiSol® 1:7 wt, showing substantially identical XRPD pattern and superimposable dissolution kinetics. The Cog 120 min VIC:AcDiSol® 1:7 wt was stable as well, but demonstrated a slightly lower ability to stabilise the disordered structures produced by cogrinding and a slight reduction of the extent of drug dissolved. Since in this coground a minor degree of drug-polymer interaction was previously attested (see for example the 1H T1 relaxation times), a certain role of the drug polymer interaction on the stabilisation of the disordered structures must be recognised. This also pointed out the importance of the selection of the appropriate grinding time for the preparation of the coground mixtures. 

4.  Conclusions 
The obtained results demonstrated that the mechanochemical activation of VIC in presence of crosslinked polymers (AcDiSol® and PVP-Cl) can be successfully used for preparing VIC in a disordered state having improved in vitro and in vivo bioavailability. Conversely, only minor changes of the solid-state features of the drug were obtained after processing VIC alone in the same operating conditions. The performed characterisations agreed to attest that drug and polymer were intimately mixed in the ground mixtures with domain average dimensions smaller than 100 Å.
The results also suggested that systems based on AcDiSol® are preferable in terms of extent and rate of drug dissolution and physical stability. Initially on the basis of a statistical analysis of the dissolution performances, two VIC:AcDiSol® coground samples have been selected from a group of 15 ones (differing for grinding time and drug-to-polymer weight ratio). Then the depth physico-chemical characterisation and the in vivo studies put in light the superiority of the Cog 180 min VIC:AcDiSol® 1:7 wt. The best system in the case of PVP-Cl resulted to be the Cog 180 min VIC:PVP-Cl 1:4 wt, whereas a higher amount of PVP-Cl gave rise to a complete disruption of the drug crystal but a worseness of the overall performance of the coground. Though both crosslinked polymers produced a pronounced enhancement of the in vivo oral bioavalaibility, very different plasma profiles were observed with the two types of coground: according to their different chemical affinity and to the presence of the drug in a different state, the AcDiSol® coground exhibited very high Cmax, followed by a quite rapid decrease of plasma concentration, whilst the PVP-Cl coground showed lower plasma concentrations, remaining flatter during the 8 h of analysis. The nanocrystalline state of the drug observed in the VIC:AcDiSol® coground was found to be unvaried for one year at ambient conditions, whilst a few signs of recrystallisation were detected in the VIC:PVP-Cl systems, with consequent variations of their dissolution performances.
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